MAPK7 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL616946	1.00	17/20
SCHEMBL617001	1.00	17/20
SCHEMBL618262	1.00	17/20
SCHEMBL619161	1.00	17/20
SCHEMBL618747	0.84	17/20
SCHEMBL616726	0.81	17/20
SCHEMBL615896	1.00	16/20
SCHEMBL619121	1.00	16/20
SCHEMBL619880	1.00	16/20
SCHEMBL617071	0.75	16/20
SCHEMBL618005	1.00	15/20
SCHEMBL618577	1.00	15/20
SCHEMBL617492	0.76	15/20
SCHEMBL616737	0.73	15/20
SCHEMBL616583	0.72	15/20
SCHEMBL616301	1.00	14/20
SCHEMBL619295	1.00	14/20
SCHEMBL618312	0.84	14/20
SCHEMBL619637	0.77	14/20
SCHEMBL618227	0.75	14/20

Clinical trials — most relevant to MAPK7 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma	PHASE4	UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer	PHASE2	COMPLETED
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma	PHASE1/PHASE2	COMPLETED
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma	PHASE2	UNKNOWN
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	PHASE2	COMPLETED
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma	PHASE1/PHASE2	COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations	PHASE2	ACTIVE_NOT_RECRUITING
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.	PHASE2	UNKNOWN
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations	PHASE2	RECRUITING
Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.	PHASE2	UNKNOWN
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma	PHASE1/PHASE2	SUSPENDED
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors	PHASE1	ACTIVE_NOT_RECRUITING
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212	PHASE1	COMPLETED
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia	PHASE1	RECRUITING
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)	PHASE1	COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer	PHASE1	COMPLETED
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma	PHASE1	COMPLETED
Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies	PHASE1	RECRUITING
ERK Inhibitor JSI-1187 in Advanced Solid Tumors	PHASE1	UNKNOWN
Effects of Mulberry Juice on Inflammatory Status and Clinical Symptoms in Patients With General Anxiety Disorder	nan	UNKNOWN
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo	nan	UNKNOWN
Glutamate Supplementation in Young Men	nan	COMPLETED
BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation	nan	COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
p38 Mitogen-Activated Protein Kinase (MAPK) and Steroid Insensitivity in Asthma	nan	COMPLETED
Molecular Analysis of Thoracic Malignancies	nan	ENROLLING_BY_INVITATION
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment	nan	ACTIVE_NOT_RECRUITING
Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection.	nan	COMPLETED
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MAPK7 binder may also engage these)

Protein	Name	Similarity
Q9WVS8	—	1.000	Q9WVS8 →
A5PKJ4	—	1.000	A5PKJ4 →
P0C865	—	1.000	P0C865 →
Q3ULB5	—	0.991	Q3ULB5 →
Q8BTW9	—	0.991	Q8BTW9 →
PAK4	Serine/threonine-protein kinase PAK 4	0.990	landscape →
O70405	—	0.990	O70405 →
Q6NSM8	—	0.989	Q6NSM8 →
Q5R8Z4	—	0.989	Q5R8Z4 →
Q3U2S4	—	0.988	Q3U2S4 →
DYRK1B	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	0.988	landscape →
Q9Z2A6	—	0.988	Q9Z2A6 →
O08919	—	0.987	O08919 →
Q8CIP4	—	0.987	Q8CIP4 →
Q9Z188	—	0.987	Q9Z188 →
O54967	—	0.987	O54967 →
Q8K3A9	—	0.987	Q8K3A9 →
Q8BHL3	—	0.986	Q8BHL3 →
O35071	—	0.986	O35071 →
PAK6	Serine/threonine-protein kinase PAK 6	0.986	landscape →
Q4V882	—	0.986	Q4V882 →
P0C1X8	—	0.986	P0C1X8 →
Q66HA1	—	0.986	Q66HA1 →
GAK	Cyclin-G-associated kinase	0.986	landscape →
Q6EU10	—	0.986	Q6EU10 →
MAP3K9	Mitogen-activated protein kinase kinase kinase 9	0.986	landscape →
Q80XI6	—	0.986	Q80XI6 →
Q2YDU3	—	0.986	Q2YDU3 →
Q6P4S6	—	0.986	Q6P4S6 →
Q76LL6	—	0.986	Q76LL6 →